This data suggests that eosinophils infiltration into IL-33-expressing tumors, may contribute to anti-tumor immune responses at earlier stages of human prostate carcinoma development, creating favorable background for ILC2 cells development and function, as well as for the future therapeutic applications related to IL-33/ILC2 axis in patients with human prostate tumors. Here, IL33 is linked to neoplasm.